LONDON - Shield Therapeutics (LON:STXS) PLC has launched a conditional offer exclusively for its existing retail shareholders in the United Kingdom (TADAWUL:4280) to purchase new ordinary shares. The offer, available through the RetailBook platform, is set at an offer price of 3.0p per share, a 5.3% premium over the closing mid-price on December 5, 2024.
The RetailBook Offer is designed to allow shareholders to invest using tax-efficient savings vehicles such as Individual Savings Accounts (ISAs) or Self-Invested Personal Pensions (SIPPs), as well as General Investment Accounts (GIAs). Notably, the offer is open only to current shareholders, with a minimum subscription of £50 per investor and a maximum issuance of 33,333,333 shares, aiming to raise gross proceeds of up to £1,000,000.
Participation in the offer is possible through a network of retail brokers and wealth managers, including AJ Bell, Hargreaves (LON:HRGV) Lansdown, and Interactive Investor. The offer is set to close at 4.30 p.m. on December 20, 2024, but may end earlier at the company's discretion or if oversubscribed.
The issuance of the new shares is contingent upon the successful completion of a separate subscription for new ordinary shares by AOP Health International Management AG and the subsequent admission of these shares to trading on the AIM segment of the London Stock Exchange (LON:LSEG). The general meeting to pass the necessary resolutions is scheduled for December 24, 2024, with an expected admission of the shares on December 30, 2024.
Shield Therapeutics values its retail shareholder base and has structured this offer to allow these shareholders to participate directly in the company's growth. The new shares will rank equally with the existing ordinary shares, including the right to dividends and other distributions declared after the issue date.
Interested shareholders must be customers of participating intermediaries and hold company shares as of the announcement date. It's important to note that once accepted, applications through intermediaries are irrevocable, and the live share price may fluctuate below the offer price.
The company has emphasized that investing in shares carries risks and advises investors to seek independent advice if necessary. The RetailBook platform will not charge any commission for applications made through this offer.
This news article is based on a press release statement from Shield Therapeutics PLC and does not constitute investment advice or an endorsement of the company's shares.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.